09:28 AM EDT, 09/11/2025 (MT Newswires) -- GRI Bio ( GRI ) said Thursday that interim data from its phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis showed no decline in lung function at six weeks.

The biotechnology company said the interim analysis, which included 24 patients, found forced vital capacity was stable when compared with baseline.

Biomarker changes suggested potential anti-fibrotic activity, with decreases in fibrosis formation markers and increases in markers of fibrosis resolution, GRI said.

No safety concerns were observed by the independent data monitoring committee, the company said.

GRI said the phase 2a study enrolled 35 patients who were randomly assigned to receive either GRI-0621 or placebo for 12 weeks, with topline data expected in Q3.

Shares of the company were up 45% in recent Thursday premarket activity.